Get the Stockscreener App
3.29
3.79%
0.12
Eupraxia Pharmaceuticals Inc stock is traded at $3.29, with a volume of 6,851.
It is up +3.79% in the last 24 hours and down -21.29% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$3.17
Open:
$3.185
24h Volume:
6,851
Relative Volume:
0.49
Market Cap:
$111.13M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-4.2727
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
+8.58%
1M Performance:
-21.29%
6M Performance:
+34.29%
1Y Performance:
+23.45%
1-Day Range:
$3.185
$3.29
1-Week Range:
$2.9622
$3.36
52-Week Range:
$2.20
$4.48
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.29 | 111.13M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
(EPRX.WT.A) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed', on November 15, 2024 - ADVFN
(EPRX) Investment Performance Report (EPRX:CA) - news.stocktradersdaily.com
TSX Penny Stock Highlights Calfrac Well Services And Two More Compelling Picks - simplywall.st
Long Term Trading Analysis for (EPRX.WT.A) - news.stocktradersdaily.com
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Closing Bell: Eupraxia Pharmaceuticals Inc WT up on Wednesday (EPRX-WT) - The Globe and Mail
When (EPRX.WT.A) Moves Investors should Listen - news.stocktradersdaily.com
Raymond James Financial Inc. Makes New $37,000 Investment in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) - Defense World
(EPRX) Proactive Strategies (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Investment Analysis and Advice - news.stocktradersdaily.com
(EPRX) Equity Trading Insights (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 1% – Should You Sell? - Defense World
(EPRX) On The My Stocks Page (EPRX:CA) - news.stocktradersdaily.com
(EPRX) Strategic Investment Report (EPRX:CA) - news.stocktradersdaily.com
(EPRX) Stock Market Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on Monday - Defense World
When (EPRX) Moves Investors should Listen (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress - MSN
Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Yahoo
Learn to Evaluate (EPRX) using the Charts (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals files report with SEC - Investing.com India
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - Weekly Voice
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results -March 20, 2025 at 05:38 pm EDT - MarketScreener
(EPRX) Equity Market Report (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% – What’s Next? - Defense World
(EPRX) Optimized Trading Opportunities (EPRX:CA) - Stock Traders Daily
How to Take Advantage of moves in (EPRX) (EPRX:CA) - Stock Traders Daily
(EPRX) Daily Stock Insights (EPRX:CA) - Stock Traders Daily
(EPRX) Stock Evaluation Report (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals is undervalued, Research Capital says - Cantech Letter
Eupraxia reports progress in EoE drug trial with promising results By Investing.com - Investing.com Canada
Medicenna Therapeutics Corp. - Baystreet.ca
Dye & Durham Limited - Baystreet.ca
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Eupraxia Pharmaceuticals Shares Rise on Positive Drug Trial Data - MarketWatch
Eupraxia Pharmaceuticals Reports Latest Updates - Investing.com
Eupraxia Pharmaceuticals Reports Latest Updates By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Inc. Announces Additional Positive Clinical Data from its Ongoing RESOLVE Phase 1b/2a Trial Evaluating EP-104GI for Treatment of Eosinophilic Esophagitis - Marketscreener.com
Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment - TipRanks
Eupraxia reports progress in EoE drug trial with promising results - Investing.com India
Eupraxia Pharmaceuticals Brief: Announcing "Positive" Data From RESOLVE Phase 1b/2a Trial Of EP-104GI For Treatment Of Eosinophilic Esophagitis - Marketscreener.com
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - The Globe and Mail
Eupraxia's EoE Drug Achieves 94% Reduction in Key Inflammatory Markers Without Steroid Side Effects - StockTitan
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Research Coverage Started at Craig Hallum - Defense World
Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential - Yahoo Finance
Craig-Hallum sets $12 target for Eupraxia stock, rates it a Buy - Investing.com Australia
Craig-Hallum sets $12 target for Eupraxia stock, rates it a Buy By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):